

The Treatment-Naive Microbiome in New-Onset Crohn's Disease

Dirk Gevers,¹ Subra Kugathasan,^{4,24} Lee A. Denson,^{5,24} Yoshiki Vázquez-Baeza,⁶ Will Van Treuren,⁷ Boyu Ren,⁸ Emma Schwager,⁸ Dan Knights,^{9,10} Se Jin Song,⁷ Moran Yassour,¹ Xochitl C. Morgan,⁸ Aleksandar D. Kostic,¹ Chengwei Luo,¹ Antonio González,⁷ Daniel McDonald,⁷ Yael Haberman,⁵ Thomas Walters,¹¹ Susan Baker,¹² Joel Rosh,¹³ Michael Stephens,¹⁴ Melvin Heyman,¹⁵ James Markowitz,¹⁶ Robert Baldassano,¹⁷ Anne Griffiths,¹⁸ Francisco Sylvester,¹⁹ David Mack,²⁰ Sandra Kim,²¹ Wallace Crandall,²¹ Jeffrey Hyams,¹⁹ Curtis Huttenhower,^{1,8} Rob Knight,^{7,22,23} and Ramnik J. Xavier^{1,2,3,*}

¹Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

²Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease

³Center for Computational and Integrative Biology

Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

⁴Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA

⁵Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA

⁶Department of Computer Science

⁷BioFrontiers Institute

University of Colorado, Boulder, CO 80309, USA

⁸Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA

⁹Department of Computer Science and Engineering, University of Minnesota, Minneapolis, MN 55108, USA

¹⁰BioTechnology Institute, University of Minnesota, St. Paul, MN 55108, USA

¹¹Division of Gastroenterology, Hepatology, and Nutrition, Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada

¹²Children's Hospital of Buffalo, Buffalo, NY 14222, USA

¹³Goryeb Children's Hospital, Morristown, NJ 07960, USA

¹⁴Mayo Clinic, Rochester, MN 55902, USA

¹⁵University of California, San Francisco, San Francisco, CA 94143, USA

¹⁶North Shore Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA

¹⁷Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

¹⁸Hospital for Sick Children, Toronto, ON M5G 1X8, Canada

¹⁹Connecticut Children's Medical Center, Hartford, CT 06106, USA

²⁰Children's Hospital of Eastern Ontario, Ottawa, ON K1H 8L1 Canada

²¹Nationwide Children's Hospital, Columbus, OH 43228, USA

²²Department of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA

²³Howard Hughes Medical Institute, Boulder, CO 80309, USA

²⁴These authors contributed equally to this work

*Correspondence: xavier@molbio.mgh.harvard.edu

<http://dx.doi.org/10.1016/j.chom.2014.02.005>

SUMMARY

Inflammatory bowel diseases (IBDs), including Crohn's disease (CD), are genetically linked to host pathways that implicate an underlying role for aberrant immune responses to intestinal microbiota. However, patterns of gut microbiome dysbiosis in IBD patients are inconsistent among published studies. Using samples from multiple gastrointestinal locations collected prior to treatment in new-onset cases, we studied the microbiome in the largest pediatric CD cohort to date. An axis defined by an increased abundance in bacteria which include Enterobacteriaceae, Pasteurellaceae, Veillonellaceae, and Fusobacteriaceae, and decreased abundance in Erysipelotrichales, Bacteroidales, and Clostridiales, correlates strongly with disease status. Microbiome comparison between CD patients with and without antibiotic exposure indicates that anti-

biotic use amplifies the microbial dysbiosis associated with CD. Comparing the microbial signatures between the ileum, the rectum, and fecal samples indicates that at this early stage of disease, assessing the rectal mucosal-associated microbiome offers unique potential for convenient and early diagnosis of CD.

INTRODUCTION

Inflammatory bowel disease (IBD) is a complex disease in which genetic and environmental circuits establish and contribute to disease pathogenesis. Recent large-scale genome-wide association studies link IBD to host-microbe pathways central to sensing/signaling and mucosal-initiated effector responses (Jostins et al., 2012). Studies of the intestinal gut microbiota imply that an unbalanced microbial community composition is associated with a dysregulated immune response (Khor et al., 2011). The microbiome thus likely plays a role in the pathogenesis of

IBD (Manichanh et al., 2012), but this role remains poorly understood. Previous studies characterized patients with established disease, but the use of small cohorts resulted in a lack of statistical power to accommodate diverse clinical covariates (Kakoussis et al., 2012), and results of these studies were likely affected by the application of treatments (Morgan et al., 2012). The existing new-onset studies that examine the fecal microbiome (Papa et al., 2012) detected a disease signal; however, because fecal bacterial ecosystems differ from those in the intestinal mucosa (Momozawa et al., 2011), studies of strictly fecal communities may face limitations in identifying microbes more directly involved in disease initiation or progression.

To improve our understanding of how the microbiota contributes to the inflammatory cascade of Crohn's disease (CD) pathogenesis, we performed a study that addresses several important limitations of previous work. We applied a standardized approach to a large, multicenter cohort of new-onset CD, collecting samples before treatment initiation, and including subjects representing the variety of disease phenotypes with respect to location, severity, and behavior. Here we report on 668 patients that include those with CD and non-IBD controls (see Table S1A available online), representing the largest single cohort microbiome study related to new-onset IBD to date as well as representing the largest characterization of mucosal-associated microbiota in non-IBD subjects. We used a combination of next-generation sequencing to deeply characterize the disease-associated microbiota, and a well-established multivariate analysis method to account for a wide range of demographic and clinical covariates (e.g., age, gender, race, disease severity, behavior, and location) (Morgan et al., 2012). The strength of this study lies in the sampling prior to treatment, the size of the cohort, and the concurrent sampling of different sites, including multiple mucosal tissue sites, and the luminal content as stool samples. Finally, we combined two additional cohorts with the RISK cohort, resulting in a total of 1,742 samples from pediatric or adult patients, with either new-onset or established disease, for which tissue biopsies and/or fecal samples were processed through a uniform sequencing and analysis approach. This multicohort study allows us to position the unique RISK cohort in the context of a comprehensively defined diversity landscape of IBD, and to identify robust and generally applicable biomarkers.

RESULTS

A Unique Treatment-Naive Inception Cohort for Pediatric CD

We studied the mucosal- and lumen-associated microbiota in a large, well-characterized inception cohort for CD in children. We included subjects from 3 to 17 years of age with a well-established diagnosis of CD ($n = 447$), and control subjects ($n = 221$) with noninflammatory conditions—for example, presenting with abdominal pain and diarrhea (Table S1A). Mucosal tissue biopsies (terminal ileum and rectum) and serum samples were collected as part of the diagnostic colonoscopic examination prior to the initiation of treatment. A subset of the enrolled patients ($n = 233$) also provided a fecal sample prior to treatment start. The diagnosis and disease categorization was confirmed after a minimum of 6 months' follow-up, and was based on a

combination of endoscopic, histological, and radiological investigations. A total of 1,321 samples, including 630 ileal and 387 rectal tissue biopsies and 304 stool samples, were submitted for microbiome profiling using 16S rRNA gene sequencing on the Illumina MiSeq platform (version 2) with 175 bp paired-end reads. After quality filtering and assembling overlapping paired-end reads, more than 45.5 million sequences were retained (mean of 29,915 sequences per sample), providing the most in-depth characterization of treatment-naive CD-associated communities to date.

The Key Players of the Microbial Dysbiosis in New-Onset Pediatric CD

An unweighted UniFrac-based comparison of the mucosal-associated microbiota from patients with new-onset CD and controls indicated that the overall diversity in microbial composition was mainly differentiated by sample type and microbial diversity, but disease phenotype was not strong enough to differentiate patients (Figure 1A). Instead, complex microbial communities from samples with multiple clinical covariates are best explored by multivariate association tests at the level of specific microbial community members. We identified microbial organisms that reached statistically significant association with subjects' disease phenotype using the MaAsLin pipeline, which identifies significant associations of the microbiota with multiple, potentially confounded sample variables (see Experimental Procedures). This has the benefit of testing for disease characteristics while controlling for several known or potential confounding variables, such as past antibiotic use, age, gender, and race. Correction for other factors that typically have a significant impact on the microbial composition, including treatment and disease duration, was not necessary, because all samples were collected prior to treatment and at standard intestinal sites regardless of the segments involved in the disease.

Biomarker detection analysis of mucosal-associated microbiome showed that inflammatory conditions were most strongly associated with an overall drop in species richness and an alteration in the abundance of several taxa (Figure 1B; Table S2, panel A). Several of these taxa have been reported in previous studies (Papa et al., 2012; Morgan et al., 2012), including Enterobacteriaceae, Bacteroidales, and Clostridiales. However, we were able to identify additional taxa as significant biomarkers for disease. Most noticeably, we detected positive correlations between CD and abundances of Pasteurellaceae (*Haemophilus* sp.), Veillonellaceae, Neisseriaceae, and Fusobacteriaceae. *Fusobacterium* has previously been suggested as a biomarker for IBD (Strauss et al., 2011) and was also recently shown to promote a beneficial microenvironment for the progression of colorectal carcinoma (Kostic et al., 2012), a long-term complication of IBD. Subsampling the data set to either smaller sample sizes or lower sequencing depths indicated that sample size contributes more substantially to the increased statistical power, highlighting the importance of sampling a large cohort. Lowering the number of sequences to 300 reads/sample (~1% of the data) did not affect our ability to detect these taxa (data not shown), but reducing to half of the samples or lower did begin to affect the recovery of some taxa (Figure S1A). Interestingly, few of these taxa were present at a higher abundance in patients under the age of 10, and were thus negatively correlated with age,




Figure 1. Most Differential Taxa in Pediatric CD

(A) A set of principal coordinate plots of the unweighted UniFrac distance, with each sample colored either by the disease phenotype (left), alpha diversity (middle), or sample type (right). PC1, PC2, and PC3 represent the top three principal coordinates that captured most of the diversity, with the fraction of diversity captured by that coordinate shown in percent.

(B) Differences in abundance are shown for the taxonomic biomarkers that were detected using a multivariate statistical approach (see [Experimental Procedures](#) and [Table S2](#)). The fold change for each taxon was calculated by dividing the mean abundance in the cases by that of the controls. Several taxonomic biomarkers measured at both the ileal and the rectal sites were found to be significantly correlated with disease phenotype; however, most of that microbial signal was lost in the stool samples. The fraction of patients that were on antibiotics during sample collection was considered as an individual subtype, due to the large confounding impact antibiotic exposure causes on the microbial composition (see [Table S2](#)). The left shows cases without antibiotic treatment, and the right includes the fraction of cases (10%) that were under antibiotic pressure at sampling. The taxa at the top are increased in disease state, whereas the taxa at the bottom follow an opposite trend. Apparent missing bars are cases in which there is no difference, or fold change equals 1. Use of antibiotics does impact the microbial composition by tipping the microbial community further toward a dysbiotic state, and has a differential impact on the taxa, depending on organism and sampling site. Related to [Figure S1](#) and [Table S1](#).

including Pasteurellaceae and Neisseriaceae ([Table S2](#), panel A; [Figure S1B](#)).

An increased level of Bacteroides and Clostridiales was maintained in non-CD patients relative to those with CD ([Table S2](#), panel A). Specific negative associations with CD were detected for several genera, including *Bacteroides*, *Faecalibacterium*, *Roseburia*, *Blautia*, *Ruminococcus*, *Coprococcus*, and a number of taxa within the families of Ruminococcaceae and Lachnospiraceae. A well-described anti-inflammatory organism that is considered to be a sensor and marker of health is *Faecalibacterium prausnitzii* ([Sokol et al., 2008](#)). Reduced ileal abundance of *F. prausnitzii* has been associated with a higher rate of endoscopic recurrence of inflammation 6 months after ileo-cecal resection.

New-Onset Mucosal-Associated Dysbiosis Is Only Weakly Reflected in Stool

The imbalance in the microbial community network was only observed in the microbiome profiles obtained from tissue samples, and was not seen in the stool samples collected at the time of the diagnosis ([Figure 1B](#)). This was confirmed by performing separate biomarker detection on the stool samples of CD patients and controls with noninflammatory conditions, resulting in only a short list of taxa significantly associated with disease. This included a gain in *Streptococcus* and a loss in a few

taxa belonging to the order of Clostridiales, including *Dorea*, *Blautia*, and *Ruminococcus* ([Table S2](#), panel B). With a mean abundance far below 0.1%, all of these taxa were minimally contributing to the overall shift. Consequently, we further investigated the precise differences between the mucosal tissue and stool samples within patients with new-onset CD ([Figure S1C](#); [Table S2](#), panel C). Of the four above-mentioned taxonomic groups that were decreased in CD, all except Bacteroidales were found to be significantly increased in stool samples, along with *Lactobacillus*, *Enterococcus*, and *Streptococcus*. In addition, the levels of Fusobacteriaceae and Neisseriaceae were reduced, but no significant differences were noted for any of the other organisms typically associated with inflammatory conditions. Based on these observations, we can infer that the microbial balance is less shifted toward a dysbiotic state in the lumen despite the disease, explaining the lack of a biomarker signal and emphasizing the need to examine tissue biopsies in addition to stool samples in order to gain a better understanding of possible mechanisms.

Antibiotic Exposure Amplifies the Microbial Dysbiosis

Antibiotic usage has previously been linked to substantial taxonomic changes in the gastrointestinal microbial composition ([Dethlefsen et al., 2008](#); [Antonopoulos et al., 2009](#); [Manichanh et al., 2010](#)). Here, a small subset of the CD patients

($n = 57/447$, 13%) was on antibiotics during sample collection, allowing a comparison between the microbiome in CD patients with and without antibiotic exposure. Although a weak effect on disease severity (PCDAI) and overall species diversity between the patient groups with and without antibiotics was found ($p = 0.043$ and 0.02 , respectively; Student's t test), we observed a strong effect on the microbial composition, and exposure to antibiotics generally amplified the dysbiosis. A more extreme impact was seen on the abundance levels of the phyla increased in noninflammatory conditions, including *Bacteroides*, *Clostridiales*, and *Erysipelotrichaceae*, which was most pronounced in rectal biopsy and stool samples, with a differential effect depending on taxa and sample type, e.g., a 10-fold increase in *Fusobacteriaceae* in the ileum and *Enterobacteriaceae* in the rectum (Figure 1B). The *Pasteurellaceae* were suppressed in the ileum, whereas the *Veillonellaceae* were decreased in the rectum and stool. We note that excluding samples from subjects with antibiotics exposure during sampling does not change the key players of the dysbiotic state outlined above (Table S2, panel 2A). These results do not provide any causative explanation but are relevant in the context of previously described associations between higher antibiotic exposure and the diagnosis of CD (Hviid et al., 2011). We hypothesize that the use of antibiotics has the potential to impact the overall community structure and increase the potential for exposure to dysbiosis.

The Functional Dysbiosis at the Mucosal Tissue Sites Reflects that of Established Disease

Shotgun sequencing for metagenomics would provide the greatest precision of microbial community assays and direct evidence of microbial function. However, nucleotide extracts of mucosal tissue samples consist of extremely high fractions (>99%) of host-derived nucleotides. In the absence of methods to efficiently dissociate the microbial from the host fraction, no cost-effective shotgun sequencing of the microbial communities can be performed. Therefore, we predicted the functional composition of these mucosal-associated microbiota using PICRUSt (Morgan et al., 2012) (Table S2, panel D). This algorithm estimates the functional potential of microbial communities given a marker gene survey and the set of currently sequenced reference genomes with an accuracy of 80%–90% on human gut communities. The functional changes in the samples of new-onset CD patients included a loss in basic biosynthesis (related to reductions in *Bacteroides* and *Clostridia*) and a switch toward pathobiont-like auxotrophy (increase in aerobic or aerotolerant taxa, i.e., *Proteobacteria* and *Pasteurellaceae*). Further, biomethanation was replaced by acetogenesis in order to reduce accumulated hydrogen. An increased disease severity further amplified the disease signal of oxidative stress and auxotrophy. Interestingly, components of the benzoate metabolic pathway were associated with disease (aminobenzoate degradation) and disease severity (fluorobenzoate degradation). Intermediaries of benzoate metabolism are known to influence microbial dysbiosis as a stress response (Eloe-Fadrosh and Rasko, 2013) and have the ability to promote *Enterobacteriaceae* growth and virulence (Freestone et al., 2007). Antibiotic exposure had several overlapping effects on the functional composition of the gut microbiota and took up one-third of all significant associations, including a unique series of pathways

related to xenobiotic metabolism (degradation of aminobenzoate, styrene, chloroalkene, toluene, benzoate, etc.).

Describing Disease Status with the Microbial Dysbiosis Index

We inferred a taxon-taxon interaction network for the ileal samples (see Experimental Procedures) and found relationships among disease-associated organisms mentioned above (Figure 2A; Table S2, panel E). Out of all significant interactions found, 52% supported a co-occurrence within the two groups of taxa that behave similarly with respect to disease (i.e., increase or decrease in CD, respectively), and 30% supported a strong co-exclusion between these two groups. Importantly, the taxa within the families *Enterobacteriaceae*, *Fusobacteriaceae*, *Pasteurellaceae*, and *Veillonellaceae* were often found together, as well as different taxa within the *Clostridia* or *Clostridia* and *Bacteroidetes* teaming up with one another. These observations led us to calculate the log of [total abundance in organisms increased in CD] over [total abundance of organisms decreased in CD] for all samples, hereafter referred to as the Microbial Dysbiosis index (MD-index). This MD-index, derived on disease phenotype, showed a strong positive correlation with clinical disease severity (PCDAI) (Figure 2B) and negative correlation with species richness (Figure 2C), demonstrating that a severe disease state manifests a strongly reduced species diversity in favor of a more extreme dysbiosis. Further, this index was a straightforward feature capturing the overall beta-diversity, resulting in a clear gradient by which samples group across all sample types (Figure 2D). This gradient reflects shifts in both groups of organisms, those increased and decreased with disease (Figure S2B). Lastly, the MD-index was also significantly higher in those patients positive for two or more microbial or cytokine serological markers ($p < 0.0001$, Student's t test). Since serologic markers are increasingly being used to help differentiate IBD disease phenotypes, such an association might indicate a potential link between the gut microbial biomarkers and the presence of these serologic biomarkers. However, with the data collected for this cohort, no specific correlations were found.

CD is characterized by inflammation spanning multiple tissue layers, with deep ulcer formation linked with worse long-term disease outcomes. The RISK cohort measured deep ulceration during the diagnostic colonoscopy, presenting us with the opportunity to examine a link between the gut microbiota and mucosal ulceration. The recorded prevalence of any deep ulcers (ileum or colon) with CD patients amounted to 42% (Table S1A). In those patients, we observed increased levels of *Pasteurellaceae* and *Veillonellaceae* ($p < 0.01$, FDR corrected $p < 0.15$) and *Rothia mucilaginosa* ($p = 0.0004$, FDR corrected $p = 0.02$). In addition, an association with the KEGG pathway for pathogenic *Escherichia coli* infection was positively associated with ulcer formation (Table S2, panel D). Further experimental study will be needed to determine whether any of these organisms are causally involved in ulceration in IBD patients, or merely adapted to live in this affected environment.

Shotgun Metagenome-Based Identification of Microbial Biomarkers

Most published studies of the microbiome in IBD so far have used a 16S rRNA gene-based approach and are thereby limited




Figure 2. The Microbial Dysbiosis Index Characterizes CD Severity

(A) A correlation network was inferred for the ileal microbiota compositions using CCREPE with a checkerboard score, indicating a strong co-occurrence between taxa of the same disease-associated behavior and a co-exclusion between taxa of a different behavior. Nodes represent the different taxa, and color corresponds to their behavior in disease, with green for those decreased in CD and red for those increased in CD. Edges between nodes represent correlations between the nodes they connect, with edge colors of dark and light gray indicating positive and negative correlations, respectively. For clarity, only edges corresponding to correlations whose similarity was less than 0.3 are shown.

(B) Scatterplot of the arcsine square root transformed abundances of all summed abundances for the taxa increased (top) or decreased (bottom) in CD, versus the pediatric CD activity index (PCDAI [Hyams et al., 1991]) as a measure for disease severity.

(C) Scatter density plot of the species richness (Chao1 [Chao et al., 2006]) versus the Microbial Dysbiosis index (MD-index) for each sample. The increase in blue color (white to dark blue) reflects the density of the scatterplot. The MD-index is defined as the log of [total abundance in organisms increased in CD] over [total abundance of organisms decreased in CD] (organisms listed in Figure 1A) and is intended as an overall summary statistic for the microbial dysbiosis described in more detail in (A). In samples with a high MD-index (>1), a strong reduction in the species richness was observed.

(D) A principal coordinate plot of the unweighted UniFrac distance, colored by the MD-index. Sqrt, square root.

Related to Figure S2 and Table S2.

in characterizing the microbiota to a resolution at the family/genus level. To study the microbiota at a higher resolution, a subset of 43 stool samples (10 controls and 33 subjects) were shotgun sequenced for metagenomics using the Illumina HiSeq2000 platform (mean 13.3 gigabases [Gb] and SD 2.5 Gb per sample, paired-end reads, fragment insert size 180 bp). Metagenomic data were filtered for human and low-quality reads, and further analyzed as described in Experimental Procedures. As indicated above, the stool samples of patients do not reflect the dysbiosis in a similar way as the mucosal tissue samples, a finding that we confirmed at both the taxonomic and the functional levels with these data (data not shown). Nevertheless, mucosal-associated organisms were not restricted to any particular intestinal location, and were readily observed in all sample types, although at lower abundances. Therefore, by adding metagenomics data on the subset of stool samples, we were able to profile the composition of microbial communities at a finer taxonomic resolution (Table S2, panel F). The dominant species increased in CD were *Escherichia coli*, *Fusobacterium nucleatum*, *Haemophilus parainfluenzae* (Pasteurellaceae), *Veillonella parvula*, *Eikenella corrodens* (Neisseriaceae), and

Gemella moribillum. The dominant species decreased in CD were *Bacteroides vulgatus*, *Bacteroides caccae*, *Bifidobacterium bifidum*, *Bifidobacterium longum*, *Bifidobacterium adolescentis*, *Bifidobacterium dentum*, *Blautia hansenii*, *Ruminococcus gnavus*, *Clostridium nexile*, *Faecalibacterium prausnitzii*, *Ruminococcus torques*, *Clostridium bolteae*, *Eubacterium rectale*, *Roseburia intestinalis*, and *Coprococcus comes*.

This detailed information and availability of genomic data will be useful in further functional characterization of these organisms and their roles in disease pathogenesis. In a first exploration, we performed a comparison between representative reference genomes for each of these species, generating a view of the differential KEGG pathways (Figure 3). The species increased in CD uniquely contributed pathway components of glycerophospholipid and lipopolysaccharide metabolism, found to instigate inflammation (Morita et al., 1999), and phosphonoacetate hydrolase, providing access to a novel carbon and phosphate source not accessible to most other organisms (Kim et al., 2011). Interestingly, the latter is a zinc-dependent enzyme that might contribute to a mineral deficiency common in newly diagnosed IBD patients. The pathway components unique to the




Figure 3. Comparative Genomics of CD Biomarkers

The KEGG metabolic pathways that differentiate the species by behavior in disease state are shown as a heatmap. A selection of reference genomes that are representative for the species increased or decreased with disease were obtained from IMG (JGI), and biomarker detection was performed on their gene content at the level of KEGG pathways. Several were statistically significant (Wilcoxon, $p < 10e-8$) and are visualized here. Related to [Table S2](#).

species decreased in CD contribute to the bile acid and amino acid biosynthesis pathways, including connections between amino acid metabolism and energy, carbohydrate, or nucleotide metabolism. Collectively, these provide access to complex carbohydrates, and the break at the alpha-ketoglutarate step of the TCA cycle is indicative of a true anaerobic lifestyle, as indicated previously ([Morgan et al., 2012](#)).

Biopsy-Associated Microbiome Can Diagnose CD

Several recent studies have explored the potential for identifying disease states based on the host-associated microbial composition, including skin swabs for psoriasis ([Statnikov et al., 2013](#)), and fecal samples for obesity ([Le Chatelier et al., 2013](#)), autism ([Hsiao et al., 2013](#)), or IBD ([Papa et al., 2012](#)). Here, we evaluated how the microbiome composition in three different sample types performed for classifying subjects by CD state using a receiver-operating characteristic (ROC) analysis. We included a total of 425 tissue biopsies of the ileum, 300 of the rectum, and 199 stool samples in three independent analyses ([Figures 4A–4C](#)). Microbiome profiles were collapsed to the genus-level abundances and normalized (see [Experimental Procedures](#)). The best performance was obtained by the ileal samples (AUC = 0.85), closely followed by the rectal biopsies (AUC = 0.78), both with a narrow confidence interval. The stool samples, however, performed less well (AUC = 0.66) and had

also a low consistency (broader confidence interval). A previous study was able to get a higher performance with stool samples for disease classification in an IBD cohort ([Papa et al., 2012](#)), but their patient cohort distinguishes itself from RISK by the fact that subjects had a mean disease duration of 34.8 months, whereas the RISK cohort is entirely new-onset, with samples only taken at the time of diagnosis. This finding is consistent with the biomarker detection analysis that indicated that several taxonomic groups were increased or decreased between cases and controls when comparing mucosal-associated microbiome profiles, but not in stool samples ([Figure 1](#)). Interestingly, classification of subjects by disease state was not affected by disease location. In this cohort, 22% had disease confined to the ileum and 25% to the colon, and 53% had ileocolonic disease. Samples from both tissue biopsy locations could classify subjects, even if disease was confined to the other location. In fact, microbiome composition between the different biopsy sites was found to be far less different than between tissue and stool, for all three disease subphenotypes ([Figure 4D](#)).

Further, this cohort presented the opportunity to derive a predictive model for future disease outcome, as patients with a positive diagnosis for CD were re-examined at a 6- and 12-month follow-up, at which point the disease activity index (PCDAI) was determined. For all patients with such follow-up data available ($n = 305$), 7.5% had an increased disease severity




Figure 4. Disease Classification Performs Well on Biopsy-Associated Microbiome Profiles

(A–C) For each of the three sample types, including terminal ileum biopsy (A), rectum biopsy (B), and stool sample (C), we evaluated the accuracy of disease classification using L1 penalized logistic regression with ROC curves representing the results. Dashed lines show the mean performance obtained when genus-level features were used, and the surrounding gray area is the 95% confidence interval. Terminal ileum biopsies performed best (AUC = 0.85), closely matched by the rectum biopsies (AUC = 0.78). However, the classifier based on the stool samples collected at the time of the diagnosis performs less well (AUC = 0.66), and with low consistency (large confidence interval).

(D) The intrasubject diversity in microbiome composition was determined for all pairwise sample type combinations. Both biopsy samples were found to be highly similar, whereas the stool sample was quite diverse. Further, we also compared whether disease location would impact the intrasubject diversity between the two tissue biopsy locations. The location of the disease, ileal (L1), colonic (L2), or ileocolonic (L3), did not significantly disrupt the similarity between the two intrasubject mucosal-associated microbiota. Also, no biomarker was detected that would allow us to distinguish these disease subphenotypes. Related to [Figure S3](#).

6 months after diagnosis, and for 22% the severity reduced from severe (PCDAI > 30) to remission (PCDAI < 10). No tissue samples were collected at later time points, and thus no follow-up mucosal microbiome profiles exist. However, we could evaluate a model for predicting whether a patient will develop an exacerbated or reduced disease severity over the next 6 months, using the microbiome and clinical covariates collected at the time of onset of disease. Using a random forests classifier trained on 90% of the data, we found we were able to predict high 6-month PCDAI (≥ 10) in the remaining 10% of the data with 67.0% accuracy, a 14% improvement over the predictive accuracy of a model trained only on clinical covariates ($52.9\% \pm 0.4\%$) ([Figure S3A](#)). Although the absolute level of accuracy is modest, the performance gain driven by the microbiome is a direct and unbiased demonstration of the utility of microbiome features for predicting clinical outcomes. To deter-

mine how influential a given feature was in building the predictive model, we tested the decrease in accuracy of the model when that feature was removed. The most influential features for predicting future PCDAI according to this test were age of onset, PCDAI at diagnosis, and levels of disease-associated organisms, including Enterobacteriaceae, *Fusobacterium*, and *Haemophilus*. Age of onset and levels of Enterobacteriaceae were negatively correlated with future PCDAI, and PCDAI at diagnosis and levels of *Fusobacterium* and *Haemophilus* were positively correlated with future PCDAI ([Figure S3B](#)).

Comparing Pediatric CD with Other Adult-Established Disease Cohorts

To position the above findings in the context of other IBD microbiome studies, we resequenced samples from a previously published study ([Morgan et al., 2012](#)) and included samples from




Figure 5. A View of the Microbial Composition across Different IBD Cohorts

We combined microbial profiles obtained for 1,742 subjects from three different IBD cohorts and generated a set of principal coordinate plots of the unweighted UniFrac distance, where each sample was colored by (A) cohort, (B) disease type, (C) MD-index, or (D) species richness (Chao1). From this combined view, it is clear that the first principal coordinate (PC1) stratifies the samples by species richness, which is negatively correlated with MD-index, and that the second principal coordinate (PC2) is largely affected by cohort. Disease phenotype is no obvious driver for sample clustering.

several other cohorts, using the same sequencing approach. Combining all of these samples resulted in data from more than 1,500 subjects, of whom 46% had CD, 31% had ulcerative colitis (UC), and 19% were non-IBD controls, and included both tissue biopsies (88%) and stool samples (12%) (Table S1B). Two important differences between the RISK cohort participants and the other cohorts were (1) the lower age range (13 years, SD 3, versus 41 years, SD 15) and (2) the fact that RISK exclusively enrolled patients with new-onset disease, whereas the mean disease duration at time of sampling in the other cohorts was 7 years since diagnosis (SD 11, range 0–62). The combined data set consisted of nearly 60 million paired-end 16S reads, with a mean of 23,620 filtered sequences per sample.

To our knowledge, this is the largest uniformly generated microbiome data set for CD specifically, but also IBD in general, revealing an extensive landscape of microbial diversity across a wide range of subjects and disease phenotypes. We therefore took the opportunity to examine the effect size of disease phenotype on the microbiome composition relative to the effects introduced by cohort, age, gender, treatment, and biopsy location. We surveyed effects on the biodiversity as a whole, and on the organisms contributing to the dysbiosis specifically, and used a linear mixed-effects model including cohort and subject as random factors (see Experimental Procedures). The results revealed that interindividual variation, cohort, and sample type had significant effects on the overall microbial community composition, and that variation introduced by disease pheno-

type and treatment was hidden underneath those primary factors (Table S2, panel G). However, within specific sample types (e.g., terminal ileum), disease can explain up to 10% of the variation seen in subsets of key dysbiotic taxa, in which the effects of having CD versus control do surface. The earlier described impact of antibiotics on the microbial community network was one of the stronger signals across all cohorts, and found in almost all included sample types. Interestingly, the signal was stronger in the mucosal-associated microbiome profiles than in the stool samples (Figure S2A). In contrast, the impact of antibiotics on

overall microbial diversity was stronger in stool than in mucosal samples, again indicating that conclusions may differ based on which sample types are studied. Taken together, this advocates for a need to standardize sample collection, include diverse sample types to represent different gastrointestinal compartments, and account for treatment effect in order to get the most statistical power to study the role of the microbiome in diseases.

Lastly, we aimed to determine the effect on individual taxa using a biomarker detection approach and compare the results across the different cohorts and disease phenotypes. Most of the organisms that were found to be increased in CD were also found to be significantly correlated with UC, but those taxa that were negatively associated with CD were not found to be significant in association with UC (Table S2, panel H). When using a weighted UniFrac distance calculation and a PCoA visualization (Figure 5), the clustering by overall microbial community composition was strongly affected by cohort (Figure 5B), and different disease subgroups significantly overlapped (Figure 5A). However, the MD-index (Figure 5C) and species richness (Figure 5D) still explained the first principal coordinate even when the different cohorts were combined and demonstrate that the specific disease-associated taxa were consistent.

DISCUSSION

Our results on the microbiome at the onset of CD have identified the key constituents of the complex gut microbial community

that define a mucosal surface in homeostasis or dysbiosis. Our work demonstrates that the creation of such a large multicenter cohort increases the resolution and statistical power for studying the role of the microbiome in disease. Several of the taxa we identified were only reliably associated with disease phenotype when using several hundreds of samples. Achieving similar sample sizes by combining independent cohorts for a cross-study comparison limits the study of parameters with large effect size that surpass the bias introduced by differences in collection and sample handling (Lozupone et al., 2013). Capturing microbial shifts in their full complexity, including taxa with smaller shifts in relative abundance comparing cases versus controls, require these large, optimal study designs.

Several of the organisms identified in this study are known to reside at the inflamed mucosa with the potential to exacerbate inflammation and/or invade intestinal epithelial cells, including strains of *Escherichia* (Rolhion and Darfeuille-Michaud, 2007) and *Fusobacterium* (Strauss et al., 2011). Others, such as *Haemophilus* and *Veillonella*, have recently been reported to contribute to oral dysbiosis in IBD patients (Said et al., 2013). *Haemophilus* spp., like the Enterobacteriaceae, are well adapted to survive in oxidative stress environments and intensify oxidative stress in airway infections (Harrison et al., 2012). Interestingly, *Veillonella* spp. are closely related to the Clostridiales, who are otherwise considered to be beneficial to the host (Furusawa et al., 2013). Prior literature, however, indicates that *Veillonella* produce lipopolysaccharides (Gupta, 2011), a gene cluster they might have gained through horizontal gene transfer (M. Fischbach, personal communication). *Rothia mucilaginosa*, here reported at increased levels in patients with intestinal ulcer formation, has been found to act as an opportunistic pathogen in immunocompromised patients (Chavan et al., 2013) and has a genomic content that is well adapted to live within the microaerophilic surface of the mucus layer in cystic fibrosis lungs (Lim et al., 2013). Most of these organisms are relatively rare in the colon, and typically part of the normal human oral and upper respiratory tract microbiota, but could become opportunistic colonizers in conditions of altered mucosal changes in tissue oxygenation and disruption of mucosal barrier function.

We observed that both the ileal and the rectal biopsy have similar discriminatory power for classifying disease, regardless of the disease location. This creates the opportunity to use a minimally invasive sampling approach that avoids bowel preparation prior to the colonoscopy, and to perform dense sampling of the mucosal-associated microbiome to monitor the response to treatment and potentially predict changes in disease flares. Being able to account more readily for the microbiota in larger cohort sizes will be of value in defining disease subphenotypes and tracking treatment effects in clinical trials, something that is currently not annotated. Understanding the microbial communities of the small intestine remains of tremendous value. Mucosal-associated microbes are uniquely positioned to influence the immune system (Belkaid and Naik, 2013); particularly, the porous mucus layer in the ileum has been shown to educate the immune system to develop tolerance toward commensals (Shan et al., 2013).

Large-scale collection of stool samples would be an even less invasive approach but for this cohort did not reflect the mucosal dysbiosis, in contrast to an earlier study (Papa et al., 2012). The

main difference between the two cohorts is that new-onset patients were sampled at the time of diagnosis. The earlier study included samples of patients with established disease (mean of 3 years at time of sampling) and a treatment history. We observed that the microbial community associated with the inflamed epithelium had an increased level of aerobic and facultative anaerobes (e.g., Proteobacteria), whereas obligate anaerobes prevailed in the feces (e.g., Bacteroides and Clostridiales). The microbial community in stool from patients with established disease also consists of less anaerobes (Papa et al., 2012). This is consistent with a recent observation that the oxygen level in the lumen increases with intestinal inflammation to such a level that gut microbiota start to shift toward an aerotolerant composition in response to an oxidative stress (Mimouna et al., 2011). In order to validate this observation, future work will need to consistently capture samples from patients across a wide range of disease durations.

Another factor affecting the gut microbial composition is the use of antibiotics, as shown in a subset of the RISK cohort patients. Previously, antibiotics have been claimed to provide benefits for CD patients as a first-line therapy. However, we question this practice based on our observation that the microbial network appears more dysbiotic in the context of antibiotic exposure. Loss of protective microbes has the potential of triggering a proliferation of less beneficial taxa (Looft and Allen, 2012), exacerbating the inflammation. Similarly, changing dietary patterns can introduce such shifts as quickly (Wu et al., 2011), particularly in those individuals with reduced microbial complexity (Fang and Evans, 2013). For example, the vitamin D pathway has importance in gut homeostasis and in signaling between the microbiota and the host immune system, and may thus have implications for the development, severity, and management of inflammation (Mouli and Ananthkrishnan, 2014).

The data presented here provide a unique framework for understanding the microbial dysbiosis in new-onset CD. This will further develop principles that are likely to govern therapeutics in IBD, but they will need to be carefully thought through (Fischbach et al., 2013). These include in particular those efforts that aim to shift the microbiome following a path that is based on the successful principles applied to recurrent *Clostridium difficile* infections, as these are unlikely to be directly applicable to the multifactorial disease pathogenesis of IBD.

EXPERIMENTAL PROCEDURES

Study Population and Sample Collection

A total of 447 children and adolescents (<17 years) with newly diagnosed CD and a control population composed of 221 subjects with noninflammatory conditions of the gastrointestinal tract were enrolled to the RISK study in 28 participating pediatric gastroenterology centers in North America between November 2008 and January 2012 (Table S1A). Biopsies were taken from the terminal ileum and rectum using standard endoscopic forceps and placed into a sterile cryovial with RNAlater (QIAGEN) on ice in the Endoscopy Suite. Nucleotides were isolated from these biopsies using the QIAGEN AllPrep Mini Kit.

16S rRNA Gene Sequencing

The 16S gene data set consists of sequences targeting the V4 variable region. Sequencing was performed on the Illumina MiSeq platform according to the manufacturer's specifications, with addition of 5% PhiX, and generating paired-end reads of 175 bp in length in each direction. The overlapping

paired-end reads were stitched together (approximately 97 bp overlap) and further processed in a data curation pipeline implemented in QIIME 1.7.0 as `pick_closed_reference_otus.py`.

Shotgun Metagenomic Sequencing

Metagenomic data production and processing were performed as described previously (HMP Consortium, 2012). In brief, library construction was performed on the Illumina HiSeq 2000 platform, targeting 7 Gb of sequence per sample with 101 bp, paired-end reads. Species abundances were calculated with MetaPhlAn 1.7.7, following Bowtie 2-2.1.0 alignment to the MetaPhlAn 1.0 unique marker database.

Statistical Analysis

Association testing of all covariates versus all taxa was performed by regressing the relative abundance of each taxon on these linear clinical covariates: subject, diagnosis, ulcerating, ileal involvement, PCDAI, biopsy location, age, gender, race, and antibiotic exposure, with subject as a random variable, using the MaAsLin algorithm with default parameters (Morgan et al., 2012).

Correlation Network

We extracted the subnetworks of microbial interactions at the terminal ileum from subjects free of any antibiotics pressure, using CCREPE (Compositionality Corrected by REnormalization and PERmutation). This is a statistical methodology for covariation analysis in compositional data developed on top of previously published work, using the NC score, a similarity measure specifically designed to detect association patterns in the human microbiome and other microbial communities (see Supplemental Information).

ROC Analysis

ROC curves were constructed to evaluate the performance of sparse logistic regression classifier (using L1 penalization) aiming to identify the IBD status of a subject based on his or her microbiome profile. We have checked the performance for classifier trained by samples from three different sites (ileum, rectum, and stool). Five ROC curves were gained per site using 5-fold cross-validation. A mean ROC curve was then given by averaging over all five individual fold ROC curves, and an approximated 95% pointwise confidence interval was also constructed by using normal approximation and the sample means and variances.

ACCESSION NUMBERS

All 16S rRNA sequences have been deposited at the National Center for Biotechnology Information as two BioProjects under ID numbers PRJNA237362 and PRJNA205152, and are also available in a variety of tables through <http://www.microbio.me/qiime/> under Study ID 2516.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, three figures, and two tables and can be found with this article at <http://dx.doi.org/10.1016/j.chom.2014.02.005>.

ACKNOWLEDGMENTS

We thank the patients who donated samples for this study, the health professionals who collected them, and the Crohn's and Colitis Foundation of America for supporting the RISK cohort. We thank Douglas Wendel, Gail Ackermann, Tim Vigers, and Tim L. Tickle for their valuable input and helpful discussions. We thank participating clinicians Marla Dubinsky, Joshua Noe, Scott Snapper, Richard Kellermayer, Michael Kappleman, Anthony Otlej, Mirian Pfefferkorn, Stanley Cohen, Stephen Guthery, Neal LeLeiko, Maria Oliva-Hemker, David Keljo, Dedrick Moulton, Barbara Kirschner, Ashish Patel, David Ziring, Jonathan Evans, Jonah Essers, Bruce Aronow, and MiOk Kim. Work was supported by grants from the Crohn's and Colitis Foundation of America, The Leona M. and Harry B. Helmsley Charitable Trust, ARO grant W911NF-11-1-0473

(C.H.), and by NIH grants U54 DE023798, R01 HG005969 (C.H.), and R01 DK092405 (R.J.X., C.H., and D.G.).

Received: December 13, 2013

Revised: January 31, 2014

Accepted: February 12, 2014

Published: March 12, 2014

REFERENCES

- Antonopoulos, D.A., Huse, S.M., Morrison, H.G., Schmidt, T.M., Sogin, M.L., and Young, V.B. (2009). Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. *Infect. Immun.* 77, 2367–2375.
- Belkaid, Y., and Naik, S. (2013). Compartmentalized and systemic control of tissue immunity by commensals. *Nat. Immunol.* 14, 646–653.
- Chao, A., Chazdon, R.L., Colwell, R.K., and Shen, T.J. (2006). Abundance-based similarity indices and their estimation when there are unseen species in samples. *Biometrics* 62, 361–371.
- Chavan, R.S., Pannaraj, P.S., Luna, R.A., Szabo, S., Adesina, A., Versalovic, J., Krance, R.A., and Kennedy-Nasser, A.A. (2013). Significant morbidity and mortality attributable to rothia mucilaginosa infections in children with hematological malignancies or following hematopoietic stem cell transplantation. *Pediatr. Hematol. Oncol.* 30, 445–454.
- Dethlefsen, L., Huse, S., Sogin, M.L., and Relman, D.A. (2008). The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol.* 6, e280.
- Eloe-Fadrosh, E.A., and Rasko, D.A. (2013). The human microbiome: from symbiosis to pathogenesis. *Annu. Rev. Med.* 64, 145–163.
- Fang, S., and Evans, R.M. (2013). Microbiology: wealth management in the gut. *Nature* 500, 538–539.
- Fischbach, M.A., Bluestone, J.A., and Lim, W.A. (2013). Cell-based therapeutics: the next pillar of medicine. *Sci. Transl. Med.* 5, 179ps177.
- Freestone, P.P., Walton, N.J., Haigh, R.D., and Lyte, M. (2007). Influence of dietary catechols on the growth of enteropathogenic bacteria. *Int. J. Food Microbiol.* 119, 159–169.
- Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* 504, 446–450.
- Gupta, R.S. (2011). Origin of diderm (Gram-negative) bacteria: antibiotic selection pressure rather than endosymbiosis likely led to the evolution of bacterial cells with two membranes. *Antonie van Leeuwenhoek* 100, 171–182.
- Harrison, A., Bakaletz, L.O., and Munson, R.S., Jr. (2012). Haemophilus influenzae and oxidative stress. *Front. Cell. Infect. Microbiol.* 2, 40.
- Hsiao, E.Y., McBride, S.W., Hsien, S., Sharon, G., Hyde, E.R., McCue, T., Codelli, J.A., Chow, J., Reisman, S.E., Petrosino, J.F., et al. (2013). Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cell* 155, 1451–1463.
- Human Microbiome Project Consortium (2012). A framework for human microbiome research. *Nature* 486, 215–221.
- Hviid, A., Svanström, H., and Frisch, M. (2011). Antibiotic use and inflammatory bowel diseases in childhood. *Gut* 60, 49–54.
- Hyams, J.S., Ferry, G.D., Mandel, F.S., Gryboski, J.D., Kibort, P.M., Kirschner, B.S., Griffiths, A.M., Katz, A.J., Grand, R.J., Boyle, J.T., et al. (1991). Development and validation of a pediatric Crohn's disease activity index. *J. Pediatr. Gastroenterol. Nutr.* 12, 439–447.
- Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., Lee, J.C., Schumm, L.P., Sharma, Y., Anderson, C.A., et al.; International IBD Genetics Consortium (IBDGC) (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 491, 119–124.
- Kaakoush, N.O., Day, A.S., Huinao, K.D., Leach, S.T., Lemberg, D.A., Dowd, S.E., and Mitchell, H.M. (2012). Microbial dysbiosis in pediatric patients with Crohn's disease. *J. Clin. Microbiol.* 50, 3258–3266.

- Khor, B., Gardet, A., and Xavier, R.J. (2011). Genetics and pathogenesis of inflammatory bowel disease. *Nature* 474, 307–317.
- Kim, A., Benning, M.M., OkLee, S., Quinn, J., Martin, B.M., Holden, H.M., and Dunaway-Mariano, D. (2011). Divergence of chemical function in the alkaline phosphatase superfamily: structure and mechanism of the P-C bond cleaving enzyme phosphonoacetate hydrolase. *Biochemistry* 50, 3481–3494.
- Kostic, A.D., Gevers, D., Pedamallu, C.S., Michaud, M., Duke, F., Earl, A.M., Ojesina, A.I., Jung, J., Bass, A.J., Taberner, J., et al. (2012). Genomic analysis identifies association of *Fusobacterium* with colorectal carcinoma. *Genome Res.* 22, 292–298.
- Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.M., Kennedy, S., et al.; MetaHIT Consortium (2013). Richness of human gut microbiome correlates with metabolic markers. *Nature* 500, 541–546.
- Lim, Y.W., Schmieder, R., Haynes, M., Furlan, M., Matthews, T.D., Whiteson, K., Poole, S.J., Hayes, C.S., Low, D.A., Maughan, H., et al. (2013). Mechanistic model of *Rothia mucilaginosa* adaptation toward persistence in the CF lung, based on a genome reconstructed from metagenomic data. *PLoS ONE* 8, e64285.
- Looft, T., and Allen, H.K. (2012). Collateral effects of antibiotics on mammalian gut microbiomes. *Gut Microbes* 3, 463–467.
- Lozupone, C.A., Stombaugh, J., Gonzalez, A., Ackermann, G., Wendel, D., Vázquez-Baeza, Y., Jansson, J.K., Gordon, J.I., and Knight, R. (2013). Meta-analyses of studies of the human microbiota. *Genome Res.* 23, 1704–1714.
- Manichanh, C., Reeder, J., Gibert, P., Varela, E., Llopis, M., Antolin, M., Guigo, R., Knight, R., and Guarner, F. (2010). Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. *Genome Res.* 20, 1411–1419.
- Manichanh, C., Borrueal, N., Casellas, F., and Guarner, F. (2012). The gut microbiota in IBD. *Nat. Rev. Gastroenterol. Hepatol.* 9, 599–608.
- Mimouna, S., Gonçalves, D., Barnich, N., Darfeuille-Michaud, A., Hofman, P., and Vouret-Craviari, V. (2011). Crohn disease-associated *Escherichia coli* promote gastrointestinal inflammatory disorders by activation of HIF-dependent responses. *Gut Microbes* 2, 335–346.
- Momozawa, Y., Deffontaine, V., Louis, E., and Medrano, J.F. (2011). Characterization of bacteria in biopsies of colon and stools by high throughput sequencing of the V2 region of bacterial 16S rRNA gene in human. *PLoS ONE* 6, e16952.
- Morgan, X.C., Tickle, T.L., Sokol, H., Gevers, D., Devaney, K.L., Ward, D.V., Reyes, J.A., Shah, S.A., LeLeiko, N., Snapper, S.B., et al. (2012). Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol.* 13, R79.
- Morita, H., Nakanishi, K., Dohi, T., Yasugi, E., and Oshima, M. (1999). Phospholipid turnover in the inflamed intestinal mucosa: arachidonic acid-rich phosphatidyl/plasmenyl-ethanolamine in the mucosa in inflammatory bowel disease. *J. Gastroenterol.* 34, 46–53.
- Mouli, V.P., and Ananthakrishnan, A.N. (2014). Review article: vitamin D and inflammatory bowel diseases. *Aliment. Pharmacol. Ther.* 39, 125–136.
- Papa, E., Docktor, M., Smillie, C., Weber, S., Preheim, S.P., Gevers, D., Giannoukos, G., Ciulla, D., Tabbaa, D., Ingram, J., et al. (2012). Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. *PLoS ONE* 7, e39242.
- Rohlfion, N., and Darfeuille-Michaud, A. (2007). Adherent-invasive *Escherichia coli* in inflammatory bowel disease. *Inflamm. Bowel Dis.* 13, 1277–1283.
- Said, H.S., Suda, W., Nakagome, S., Chinen, H., Oshima, K., Kim, S., Kimura, R., Iraha, A., Ishida, H., Fujita, J., et al. (2013). Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. *DNA Res.* 21, 15–25.
- Shan, M., Gentile, M., Yeiser, J.R., Walland, A.C., Bornstein, V.U., Chen, K., He, B., Cassis, L., Bigas, A., Cols, M., et al. (2013). Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. *Science* 342, 447–453.
- Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L.G., Gratadoux, J.J., Blugeon, S., Bridonneau, C., Furet, J.P., Corthier, G., et al. (2008). *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc. Natl. Acad. Sci. USA* 105, 16731–16736.
- Statnikov, A., Alekseyenko, A.V., Li, Z., Henaff, M., Perez-Perez, G.I., Blaser, M.J., and Aliferis, C.F. (2013). Microbiomic signatures of psoriasis: feasibility and methodology comparison. *Sci. Rep.* 3, 2620.
- Strauss, J., Kaplan, G.G., Beck, P.L., Rioux, K., Panaccione, R., Deviney, R., Lynch, T., and Allen-Vercoe, E. (2011). Invasive potential of gut mucosa-derived *Fusobacterium nucleatum* positively correlates with IBD status of the host. *Inflamm. Bowel Dis.* 17, 1971–1978.
- Wu, G.D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.Y., Keilbaugh, S.A., Bewtra, M., Knights, D., Walters, W.A., Knight, R., et al. (2011). Linking long-term dietary patterns with gut microbial enterotypes. *Science* 334, 105–108.